Adjunctive pharmacotherapy in the treatment of alcohol and drug dependence

Evidence-Based Addiction Treatment

Volumn , Issue , 2009, Pages 287-310

  Swift, Robert ^a   Leggio, Lorenzo ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650239106     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374348-0.00015-X     Document Type: Chapter

References (91)

1. Addolorato G., Caputo F., Capristo E., Domenicali M., Bernardi M., Janiri L., et al. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol and Alcoholism 2002, 37:504-508.
2. Addolorato G., Leggio L., Abenavoli L., Gasbarrini G. Neurobiochemical and clinical aspects of craving in alcohol addiction: A review. Addictive Behaviors 2005, 30:1209-1224. amp; Alcoholism Treatment Study Group.
3. Addolorato G., Leggio L., Ferrulli A., Cardone S., Vonghia L., Mirijello A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.
4. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA 2006, 295:2003-2017.
5. Anton R.F., Oroszi G., O'Malley S., Couper D., Swift R., Pettinati H., et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry 2008, 65:135-144.
6. Bouza C., Angeles M., Muñoz A., Amate J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 2004, 99:811-828.
7. Brewer C. Recent developments in disulfiram treatment. Alcohol and Alcoholism 1993, 28:383-395.
8. Cahill K., Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database of Systematic Reviews 2007, 6(Issue 4.). Art. No.: CD005353.
9. Capone T., Brahen L., Condren R., Kordal N., Melchionda R., Peterson M. Retention and outcome in a narcotic antagonist treatment program. Journal of Clinical Psychology 1986, 42:825-833.
10. Carroll K.M., Nich C., Ball S.A., McCance E., Frankforter T.L., Rounsaville B.J. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: Sustained effects of treatment. Addiction 2000, 95:1335-1349.
11. Chick J., Anton R., Checinski K., Croop R., Drummond D.C., Farmer R., et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol and Alcoholism 2000, 35:587-593.
12. Chick J., Gough K., Falkowski W., Kershaw P., Hore B., Mehta B., et al. Disulfiram treatment of alcoholism. British Journal of Psychiatry 1992, 161:84-89.
13. Code of Federal Regulations (42 CFR, Part 8). Certification of Opioid Treatment Programs.
14. Comer S.D., Sullivan M.A., Yu E., Rothenberg J.L., Kleber H.D., Kampman K., et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Archives of General Psychiatry 2006, 63:210-218.
15. Dackis C.A., Lynch K.G., Yu E., Samaha F.F., Kampman K.M., Cornish J.W., et al. Modafinil and cocaine: A double-blind, placebo-controlled drug interaction study. Drug and Alcohol Dependence 2003, 70:29-37.
16. D'Aunno T., Pollack H.A. Changes in methadone treatment practices: Results from a national panel study, 1988-2000. JAMA 2002, 288:850-856.
17. Davidson D., Swift R.M., Fitz E. Naltrexone increases the latency to drink alcohol in social drinkers. Alcoholism: Clinical and Experimental Research 1996, 20:732-739.
18. de Wildt W.A., Schippers G.M., Van Den Brink W., Potgieter A.S., Deckers F., Bets D. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems?. Alcohol and Alcoholism 2002, 37:375-382.
19. Dole V.P., Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: Clinical trial with methadone hydrochloride. JAMA 1965, 193:646-650.
20. Donovan D.M., Anton R.F., Miller W.R., Longabaugh R., Hosking J.D., Youngblood M., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE study): Examination of posttreatment drinking outcomes. Journal of Studies on Alcohol and Drugs 2008, 69:5-13.
21. Eisenberg M.J., Filion K.B., Yavin D., Bélisle P., Mottillo S., Joseph L., et al. Pharmacotherapies for smoking cessation: A meta-analysis of randomized controlled trials. Canadian Medical Association Journal 2008, 179:135-144.
22. Feeney G.F., Connor J.P., Young R.M., Tucker J., McPherson A. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: A single centres' experience with pharmacotherapy. Alcohol and Alcoholism 2006, 41:321-327.
23. Fiore, M. C., Jaén, C. R., Baker, T. B., et al. (May 2008). Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service.
24. Fuller R.K., Branchley L., Brightwell D.R., Derman R.M., Emrick C.D., Iber F.L., et al. Disulfiram treatment of alcoholism: A Veterans Administration cooperative study. JAMA 1986, 256:1449-1455.
25. Garbutt J.C., Kranzler H.R., O'Malley S.S., Gastfriend D.R., Pettinati H.M., Silverman B.L., et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005, 293:1617-1625.
26. Hays J.T., Hurt R.D., Rigotti N.A., Niaura R., Gonzales D., Durcan M.J., et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: A randomized, controlled trial. Annals of Internal Medicine 2001, 135:423-433.
27. Heidbreder C.A., Hagan J.J. Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Current Opinion in Pharmacology 2005, 5:107-118.
28. Higgins S.T. Some potential contributions of reinforcement and consumer-demand theory to reducing cocaine use. Addictive Behavior 1996, 21:803-816.
29. Hughes J.R., Goldstein M.G., Hurt R.D., Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999, 281:72-76.
30. Hurt R.D., Sachs D.P., Glover E.D., Offord K.P., Johnston J.A., Dale L.C., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. New England Journal of Medicine 1997, 337:1195-1202.
31. Hutchison K.E., Ray L., Sandman E., Rutter M.C., Peters A., Davidson D., et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 2006, 31:1310-1317.
32. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., et al. Oral topiramate for treatment of alcohol dependence: A randomised controlled trial. Lancet 2003, 361:1677-1685.
33. Johnson B.A., Roache J.D., Javors M.A., DiClemente C.C., Cloninger C.R., Prihoda T.J., et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000, 284:963-971.
34. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., et al. Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA 2007, 298:1641-1651.
35. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine 1999, 340:685-691.
36. Kakko J., Grönbladh L., Svanborg K.D., von Wachenfeldt J., Rück C., Rawlings B., et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. American Journal of Psychiatry 2007, 164:797-803.
37. Kampman K.M., Pettinati H., Lynch K.G., Dackis C., Sparkman T., Weigley C., O'Brien C.P. A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence 2004, 75:233-240.
38. Kampman K.M., Pettinati H.M., Lynch K.G., Whittingham T., Macfadden W., Dackis C., et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. Journal of Clinical Psychopharmacology 2007, 27:344-351.
39. Kiefer F., Jahn H., Tarnaske T., Helwig H., Briken P., Holzbach R., et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Archives of General Psychiatry 2003, 60:92-99.
40. Koob G.F. The neurobiology of addiction: A neuroadaptational view relevant for diagnosis. Addiction 2006, 101(Suppl 1):23-30.
41. Koob G.F. Alcoholism: Allostasis and beyond. Alcoholism: Clinical and Experimental Research 2006, 27:232-243.
42. Kosten T.R., Kleber H.D. Strategies to improve compliance with narcotic antagonists. American Journal of Drug and Alcohol Abuse 1984, 10:249-266.
43. Kranzler H.R., Wesson D.R., Billot L. Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical and Experimental Research 2004, 28:1051-1059.
44. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., Rosenheck R.A. Naltrexone in the treatment of alcohol dependence. New England Journal of Medicine 2001, 345:1734-1739. amp; Veterans Affairs Naltrexone Cooperative Study 425 Group.
45. Lappalainen J., Kranzler H.R., Malison R., Price L.H., Van Dyck C., Rosenheck R.A., et al. A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Archives of General Psychiatry 2002, 59:825-831.
46. Le Foll B., George T.P. Treatment of tobacco dependence: Integrating recent progress into practice. Canadian Medical Association Journal 2007, 177:1373-1380.
47. Leggio L., Kenna G.A., Swift R.M. New developments for the pharmacological treatment of alcohol withdrawal syndrome: A focus on non-benzodiazepine GABAergic medications. Progress in Neuropsychopharmacology and Biological Psychiatry 2008, 32:1106-1117.
48. Ling W., Rawson R.A., Compton P.A. Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine. Journal of Psychoactive Drugs 1994, 26:119-128.
49. Mann K., Lehert P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcoholism: Clinical and Experimental Research 2004, 28:51-63.
50. Mason B.J., Goodman A.M., Chabac S., Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. Journal of Psychiatric Research 2006, 40:383-393.
51. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opiate replacement therapy for opiate dependence. Cochrane Database of Systematic Reviews 2003 2003, CD002209.
52. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness, implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
53. Monti P., Rohsenow D., Hutchison K., Swift R.M., Mueller T.I., Colby S.M., et al. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcoholism: Clinical and Experimental Research 1999, 23:1386-1394.
54. Monti P.M., Rohsenow D.J., Swift R., Gulliver S.B., Colby S.M., Mueller T.I., et al. Naltrexone and cue-exposure with coping and communications skills training for alcoholics: Treatment process and one-year outcomes. Alcoholism: Clinical and Experimental Research 2001, 25:1634-1647.
55. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001, 2:119-128.
56. NIAAA (2007). Helping patients who drink too much: A clinician's guide. NIAAA NIH Government Publications 2007 Edition. Available at . http://www.niaaa.nih.gov/publications/Practitioner/guide.pdf.
57. Nides M., Oncken C., Gonzales D., Rennard S., Watsky E.J., Anziano R., et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine 2006, 166:1561-1568.
58. O'Brien C.P. Anticraving medications for relapse prevention: A possible new class of psychoactive medications. American Journal of Psychiatry 2005, 162:1423-1431.
59. O'Farrell T.J., Allen J.P., Litten R.Z. Disulfiram (antabuse) contracts in treatment of alcoholism. NIDA Research Monograph 1995, 150:65-91.
60. O'Malley S.S., Carroll K.M. Psychotherapeutic considerations in pharmacological trials. Alcoholism: Clinical and Experimental Research 1996, 20(7 Suppl):17A-22A.
61. O'Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry 1992, 49:881-887.
62. O'Malley S.S., Rounsaville B.J., Farren C., Namkoong K., Wu R., Robinson J., et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: A nested sequence of 3 randomized trials. Archives of Internal Medicine 2003, 163:1695-1704.
63. Oncken C., Gonzales D., Nides M., Rennard S., Watsky E., Billing C.B., et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine 2006, 166:1571-1577.
64. Oslin D.W., Berrettini W., Kranzler H.R., Pettinati H., Gelernter J., Volpicelli J.R., et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28(8):1546-1552.
65. Paille F.M., Guelfi J.D., Perkins A.C., Royer R.J., Steru L., Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol and Alcoholism 1995, 30:239-247.
66. Pelc I., Ansoms C., Lehert P., Fischer F., Fuchs W.J., Landron F., et al. The European NEAT program: An integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcoholism, Clinical and Experimental Research 2002, 26:1529-1538.
67. Pelc I., Verbanck P., LeBon O., Gavrilovic M., Lion K., Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: A 90-day placebo-controlled dose finding study. British Journal of Psychiatry 1997, 171:73-77.
68. Pettinati H.M., Volpicelli J.R., Pierce J.D., O'Brien C.P. Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases 2000, 19(1):71-83.
69. Resnick R.B., Schuyten-Resnick E., Washton A.M. Assessment of narcotic antagonists in the treatment of opioid dependence. Annual Review of Pharmacology and Toxicology 1980, 20:463-474.
70. Robinson T.E., Berridge K.C. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research Reviews 1993, 18:247-291.
71. Rounsaville B.J., Gawin F.H., Kleber H.D. Interpersonal psychotherapy adapted for ambulatory cocaine users. American Journal of Drug and Alcohol Abuse 1985, 11:171.
72. Sass H., Soyka M., Mann K., Zieglgansberger W. Relapse prevention by acamprosate: Results from a placebo controlled study on alcohol dependence. Archives of General Psychiatry 1996, 53:673-680.
73. Schroeder J.P., Overstreet D.H., Hodge C.W. The neuropeptide-Y Y5 receptor antagonist L-152,804 decreases alcohol self-administration in inbred alcohol-preferring (iP) rats. Alcohol 2005, 36:179-186.
74. Senay E.C. Methadone maintenance treatment. International Journal of the Addictions 1985, 20:803-821.
75. Shoptaw S., Yang X., Rotheram-Fuller E.J., Hsieh Y.-C., Kintaudie P.C., Charuvastra V.C., et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. Journal of Clinical Psychiatry 2003, 64:1440-1448.
76. Silagy C., Lancaster T., Stead L., Mant D., Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2004 2004, (3). CD000146.
77. Soyka M., Preuss U., Schuetz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism: Results from a non-blind, multicentre study. Drugs R&D 2002, 3:1-12.
78. Srisurapanont M., Jarusuraisin N. Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology 2005, 8:267-280.
79. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry 1994, 151:1025-1030.
80. Suh J.J., Pettinati H.M., Kampman K.M., O'Brien C.P. The status of disulfiram: A half of a century later. Journal of Clinical Psychopharmacology 2006, 26:290-302.
81. Swift R. Emerging approaches to managing alcohol dependence. American Journal of Health-System Pharmacy 2007, 64(5 Suppl 3):S12-S22.
82. Swift R.M. Drug therapy for alcohol dependence. New England Journal of Medicine 1999, 340:1482-1490.
83. Swift R.M., Whelihan W., Kuznetsov O., Buongiorno G., Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. American Journal of Psychiatry 1994, 151:1463-1467.
84. Thomas C.P., Wallack S.S., Lee S., McCarty D., Swift R. Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment 2003, 24:1-11.
85. Thomas S.E., Miller P.M. Knowledge and attitudes about pharmacotherapy for alcoholism: A survey of counselors and administrators in community-based addiction treatment centres. Alcohol and Alcoholism 2007, 42:113-118.
86. Vocci F.J., Acri J., Elkashef A. Medication development for addictive disorders: The state of the science. American Journal of Psychiatry 2005, 162:1432-1440.
87. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 1992, 49:876-880.
88. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., O'Brien C.P. Naltrexone and alcohol dependence: Role of subject compliance. Archives of General Psychiatry 1997, 54:737-742.
89. Volpicelli J.R., Watson N.T., King A.C., Sherman C., O'Brien C.P. Effect of naltrexone on alcohol "high" in alcoholics. American Journal of Psychiatry 1995, 152:613-615.
90. Weiss R.D., Kueppenbender K.D. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. Journal of Clinical Psychopharmacology 2006, 26(Suppl 1):S37-S42.
91. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychological Reviews 1987, 94(4):469-492.